We are focusing on areas of oncology, autoimmune diseases and metabolic disorders to address unmet medical needs. Within our clinical-stage pipeline, our core products TYK2 inhibitor D-2570 and oral SERD taragarestrant (D-0502) are both advancing through Phase III registration trials, while our URAT1 inhibitor darbinurad (D-0120) has completed a Phase IIb clinical trial. In addition, we maintain a robust pipeline of preclinical candidates, including the WRN inhibitor YF087, the KIF18A inhibitor YF550, and the oral STAT6 degrader YF057.